GSK fined US$3b for healthcare fraud
Panadol maker GlaxoSmithKline has agreed to pay US$3 billion in fines for marketing drugs for unauthorised uses, holding back safety data, and cheating the US government’s Medicaid program. GSK targeted the antidepressant Paxil to patients under age 18 when it was approved for adults only, and pushed the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction. [source]